Where is the antibiotics market heading? Many opportunities exist in that industry and market, particularly with the development of new classes of antibacterial drug. In particular, treatments targeting C. difficile and MRSA infections will make a difference to 2022.
Patent expiries will challenge antibiotic manufacturers throughout this decade, with generic pharmaceutical sales prominent and growing. Companies will use product lifecycle management to reduce declines of brands and stimulate their sales, our analysis shows.
What about product launches, new drug classes and expanded indications? The antibacterial R&D pipeline has limitations but holds promise. You find out how leading companies can contribute to our predicted growth and renewal of the market to 2022.
In 2012, more than 50 product candidates are in clinical trials. There are many opportunities for collaborations and in-licensing. Many under-met treatment needs exist.
Which companies are best placed to harness opportunities in the discovery, development, manufacturing and marketing of antibacterial medicines? Our study shows you and explains.Company analyses, revenue forecasts, R&D and discussions of industry prospects
In visiongain's report you find historical revenues, sales predictions, growth rates and market breakdowns. Also, you see discussions of companies, product portfolios, R&D, commercial news and revenue potentials. You receive 95 tables and 66 charts.Ten ways Top 20 Antibacterial Drug Manufacturers 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:• Assess 20 leading antibacterial drug manufacturers, discovering their activities and outlooks from 2012• Discover overall world market and s
Copyright©2012 PR Newswire.
All rights reserved